Clinical outcomes of radical prostatectomy in patients with prostate cancer

Kunihiro Nozaki, Seiji Kai, Tadashi Oeda

Research output: Contribution to journalArticle

Abstract

We investigated the clinical outcomes of radical prostatectomy in patients with prostate cancer. This study included 101 men with prostate cancer who underwent radical prostatectomy between 1998 and 2007. Cancer-specific survival, predictors of prostate-specific antigen (PSA) failure, and incidence of clinically insignificant cancer were retrospectively analyzed. PSA failure was defined as a PSA level greater than 0.2 ng/ml. Clinically Tl cancers smaller than 0.5 ml with a Gleason score of 6 or less were defined as clinically insignificant cancer. Median follow-up was 60 months (range, 1-133 months). Twenty-five (25%) of the 101 patients underwent adjuvant therapy such as radiotherapy or androgen deprivation therapy, however, only one (1%) patient died of prostate cancer. The 5-year cancer-specific survival was 100%. PSA failure was confirmed in 26 (34%) of the 76 patients who did not undergo any adjuvant therapy. In univariate analysis, PSA 10 < ng/ml (P = 0.0013), pathological stage T3 (P = 0.013), and positive surgical margin (P = 0.0016) were predictors of PSA failure. Clinically insignificant cancers were identified in 4 (4%) patients. Since two of them were defined as a high-risk group at preoperative assessment, it was still difficult to predict these cancers before surgery. The incidence of clinically insignificant cancer was relatively low, and even in high-risk prostate cancer patients, the clinical outcomes of radical prostatectomy were excellent with adequate adjuvant therapy, and accordingly most prostate cancer patients should undergo treatment.

Original languageEnglish
Pages (from-to)404-409
Number of pages6
JournalNishinihon Journal of Urology
Volume73
Issue number8
Publication statusPublished - Aug 2011
Externally publishedYes

Fingerprint

Prostatectomy
Prostatic Neoplasms
Prostate-Specific Antigen
Neoplasms
Therapeutics
Survival
Neoplasm Grading
Incidence
Androgens
Radiotherapy

Keywords

  • Clinically insignificant cancer
  • Prostate cancer
  • PSA failure
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Clinical outcomes of radical prostatectomy in patients with prostate cancer. / Nozaki, Kunihiro; Kai, Seiji; Oeda, Tadashi.

In: Nishinihon Journal of Urology, Vol. 73, No. 8, 08.2011, p. 404-409.

Research output: Contribution to journalArticle

Nozaki, Kunihiro ; Kai, Seiji ; Oeda, Tadashi. / Clinical outcomes of radical prostatectomy in patients with prostate cancer. In: Nishinihon Journal of Urology. 2011 ; Vol. 73, No. 8. pp. 404-409.
@article{7b91ca2543154e9eb807c7649799be39,
title = "Clinical outcomes of radical prostatectomy in patients with prostate cancer",
abstract = "We investigated the clinical outcomes of radical prostatectomy in patients with prostate cancer. This study included 101 men with prostate cancer who underwent radical prostatectomy between 1998 and 2007. Cancer-specific survival, predictors of prostate-specific antigen (PSA) failure, and incidence of clinically insignificant cancer were retrospectively analyzed. PSA failure was defined as a PSA level greater than 0.2 ng/ml. Clinically Tl cancers smaller than 0.5 ml with a Gleason score of 6 or less were defined as clinically insignificant cancer. Median follow-up was 60 months (range, 1-133 months). Twenty-five (25{\%}) of the 101 patients underwent adjuvant therapy such as radiotherapy or androgen deprivation therapy, however, only one (1{\%}) patient died of prostate cancer. The 5-year cancer-specific survival was 100{\%}. PSA failure was confirmed in 26 (34{\%}) of the 76 patients who did not undergo any adjuvant therapy. In univariate analysis, PSA 10 < ng/ml (P = 0.0013), pathological stage T3 (P = 0.013), and positive surgical margin (P = 0.0016) were predictors of PSA failure. Clinically insignificant cancers were identified in 4 (4{\%}) patients. Since two of them were defined as a high-risk group at preoperative assessment, it was still difficult to predict these cancers before surgery. The incidence of clinically insignificant cancer was relatively low, and even in high-risk prostate cancer patients, the clinical outcomes of radical prostatectomy were excellent with adequate adjuvant therapy, and accordingly most prostate cancer patients should undergo treatment.",
keywords = "Clinically insignificant cancer, Prostate cancer, PSA failure, Radical prostatectomy",
author = "Kunihiro Nozaki and Seiji Kai and Tadashi Oeda",
year = "2011",
month = "8",
language = "English",
volume = "73",
pages = "404--409",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "8",

}

TY - JOUR

T1 - Clinical outcomes of radical prostatectomy in patients with prostate cancer

AU - Nozaki, Kunihiro

AU - Kai, Seiji

AU - Oeda, Tadashi

PY - 2011/8

Y1 - 2011/8

N2 - We investigated the clinical outcomes of radical prostatectomy in patients with prostate cancer. This study included 101 men with prostate cancer who underwent radical prostatectomy between 1998 and 2007. Cancer-specific survival, predictors of prostate-specific antigen (PSA) failure, and incidence of clinically insignificant cancer were retrospectively analyzed. PSA failure was defined as a PSA level greater than 0.2 ng/ml. Clinically Tl cancers smaller than 0.5 ml with a Gleason score of 6 or less were defined as clinically insignificant cancer. Median follow-up was 60 months (range, 1-133 months). Twenty-five (25%) of the 101 patients underwent adjuvant therapy such as radiotherapy or androgen deprivation therapy, however, only one (1%) patient died of prostate cancer. The 5-year cancer-specific survival was 100%. PSA failure was confirmed in 26 (34%) of the 76 patients who did not undergo any adjuvant therapy. In univariate analysis, PSA 10 < ng/ml (P = 0.0013), pathological stage T3 (P = 0.013), and positive surgical margin (P = 0.0016) were predictors of PSA failure. Clinically insignificant cancers were identified in 4 (4%) patients. Since two of them were defined as a high-risk group at preoperative assessment, it was still difficult to predict these cancers before surgery. The incidence of clinically insignificant cancer was relatively low, and even in high-risk prostate cancer patients, the clinical outcomes of radical prostatectomy were excellent with adequate adjuvant therapy, and accordingly most prostate cancer patients should undergo treatment.

AB - We investigated the clinical outcomes of radical prostatectomy in patients with prostate cancer. This study included 101 men with prostate cancer who underwent radical prostatectomy between 1998 and 2007. Cancer-specific survival, predictors of prostate-specific antigen (PSA) failure, and incidence of clinically insignificant cancer were retrospectively analyzed. PSA failure was defined as a PSA level greater than 0.2 ng/ml. Clinically Tl cancers smaller than 0.5 ml with a Gleason score of 6 or less were defined as clinically insignificant cancer. Median follow-up was 60 months (range, 1-133 months). Twenty-five (25%) of the 101 patients underwent adjuvant therapy such as radiotherapy or androgen deprivation therapy, however, only one (1%) patient died of prostate cancer. The 5-year cancer-specific survival was 100%. PSA failure was confirmed in 26 (34%) of the 76 patients who did not undergo any adjuvant therapy. In univariate analysis, PSA 10 < ng/ml (P = 0.0013), pathological stage T3 (P = 0.013), and positive surgical margin (P = 0.0016) were predictors of PSA failure. Clinically insignificant cancers were identified in 4 (4%) patients. Since two of them were defined as a high-risk group at preoperative assessment, it was still difficult to predict these cancers before surgery. The incidence of clinically insignificant cancer was relatively low, and even in high-risk prostate cancer patients, the clinical outcomes of radical prostatectomy were excellent with adequate adjuvant therapy, and accordingly most prostate cancer patients should undergo treatment.

KW - Clinically insignificant cancer

KW - Prostate cancer

KW - PSA failure

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=80052973871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052973871&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 404

EP - 409

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 8

ER -